News articles about ShangPharma (NYSE:SHP) have trended somewhat positive on Thursday, Accern reports. The research group ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ShangPharma earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.0984145511026 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of ShangPharma traded down $700.00, reaching $23,000.00, during mid-day trading on Thursday, according to Marketbeat. The stock had a trading volume of 25,960 shares.
ShangPharma Company Profile
ShangPharma Corporation (ShangPharma) is a China-based holding company. The Company is a pharmaceutical and biotechnology research and development (R&D) outsourcing company. It provides a range of high-quality, integrated services across the drug discovery and development process to international and Chinese pharmaceutical and biotechnology companies.
Receive News & Ratings for ShangPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShangPharma and related companies with MarketBeat.com's FREE daily email newsletter.